Severe Atypical Iliac Wing Fracture Associated with Long-term Bisphosphonate Use

Overview

Journal Skeletal Radiol

Specialties Orthopedics
Radiology

Date 2024 Jul 20

PMID 39031177

Authors

John Kelliher

George Rahmani

John J Carey

Diane Bergin

Affiliations

Soon will be listed here.

Abstract

Background: Bisphosphonate use is associated with atypical non-traumatic fractures, which are most commonly seen in the femur.

Case Presentation: We report a 63-year-old postmenopausal woman who presented acutely with progressively worsening lumbar pain radiating to her left hip for 10 days. There was no antecedent trauma. On examination, the patient could not bear weight on her left leg due to the severity of the pain. Radiography and computed tomography of the pelvis demonstrated an iliac wing fracture which was treated conservatively. The patient had a significant past medical history of breast cancer and intense bisphosphonate use for several years which was discontinued 3 years previously. No discrete bone lesion was seen at the fracture site on computed tomography, and there was no evidence of metastatic disease elsewhere. A dual-energy X-ray absorptiometry scan showed the lowest bone mineral density T-score of - 1.2. A diagnosis of an atypical fracture related to long-term bisphosphonate therapy was made.

Conclusion: To the best of our knowledge, this is the first reported case of an isolated iliac wing fracture associated with long-term bisphosphonate therapy in the literature. Whilst the incidence of such fractures is exceedingly rare, it is an important differential in patients with atypical fractures on long-term bisphosphonates.

References

Black D, Geiger E, Eastell R, Vittinghoff E, Li B, Ryan D . Atypical Femur Fracture Risk versus Fragility Fracture Prevention with Bisphosphonates. N Engl J Med. 2020; 383(8):743-753. PMC: 9632334. DOI: 10.1056/NEJMoa1916525. View

Gedmintas L, Solomon D, Kim S . Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res. 2013; 28(8):1729-37. PMC: 3713078. DOI: 10.1002/jbmr.1893. View

Shane E, Burr D, Abrahamsen B, Adler R, Brown T, Cheung A . Atypical subtrochanteric and diaphyseal femoral fractures: second report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2013; 29(1):1-23. DOI: 10.1002/jbmr.1998. View

Schilcher J, Aspenberg P . Incidence of stress fractures of the femoral shaft in women treated with bisphosphonate. Acta Orthop. 2009; 80(4):413-5. PMC: 2823197. DOI: 10.3109/17453670903139914. View

Watson H, Hopper G, Gupta S, Roberts J . Pathological pelvic fracture following long-term bisphosphonate use in a 63-year-old woman. BMJ Case Rep. 2014; 2014. PMC: 4195048. DOI: 10.1136/bcr-2014-206319. View

Odvina C, Zerwekh J, Rao D, Maalouf N, Gottschalk F, Pak C . Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab. 2004; 90(3):1294-301. DOI: 10.1210/jc.2004-0952. View

Patel V, Graves L, Lukert B . Pelvic fractures associated with long-term bisphosphonate therapy - case report. J Musculoskelet Neuronal Interact. 2013; 13(2):251-4. View

Black D, Abrahamsen B, Bouxsein M, Einhorn T, Napoli N . Atypical Femur Fractures: Review of Epidemiology, Relationship to Bisphosphonates, Prevention, and Clinical Management. Endocr Rev. 2018; 40(2):333-368. DOI: 10.1210/er.2018-00001. View

Armamento-Villareal R, Napoli N, Diemer K, Watkins M, Civitelli R, Teitelbaum S . Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif Tissue Int. 2009; 85(1):37-44. DOI: 10.1007/s00223-009-9263-5. View

Imai K, Yamamoto S, Anamizu Y, Horiuchi T . Pelvic insufficiency fracture associated with severe suppression of bone turnover by alendronate therapy. J Bone Miner Metab. 2007; 25(5):333-6. DOI: 10.1007/s00774-007-0771-y. View

Hadji P . Aromatase inhibitor-associated bone loss in breast cancer patients is distinct from postmenopausal osteoporosis. Crit Rev Oncol Hematol. 2008; 69(1):73-82. DOI: 10.1016/j.critrevonc.2008.07.013. View

10.

Coleman R, Marshall H, Cameron D, Dodwell D, Burkinshaw R, Keane M . Breast-cancer adjuvant therapy with zoledronic acid. N Engl J Med. 2011; 365(15):1396-405. DOI: 10.1056/NEJMoa1105195. View

11.

Bone H, Greenspan S, McKeever C, Bell N, Davidson M, Downs R . Alendronate and estrogen effects in postmenopausal women with low bone mineral density. Alendronate/Estrogen Study Group. J Clin Endocrinol Metab. 2000; 85(2):720-6. DOI: 10.1210/jcem.85.2.6393. View

12.

Cheung A, McKenna M, van de Laarschot D, Zillikens M, Peck V, Srighanthan J . Detection of Atypical Femur Fractures. J Clin Densitom. 2019; 22(4):506-516. DOI: 10.1016/j.jocd.2019.07.003. View

13.

Deas C, Murphy P, Iranikhah M, Freeman M . Retained Skeletal Effects of Zoledronic Acid Following Discontinuation of Treatment: A Review of the Literature. Consult Pharm. 2017; 32(3):144-155. DOI: 10.4140/TCP.n.2017.144. View